Abstract
Relevance. Among the groups at high risk of developing invasive pneumococcal infections, patients with multiple myeloma (MM) stand out among the highest rates of morbidity and mortality due to the presence of profound immunosuppression. Aims: to outline the current state of the problem of vaccine prevention of pneumococcal infection in patients receiving treatment for multiple myeloma, to present the evidence base for vaccination with conjugated pneumococcal vaccine. A continuous data review method was used to evaluate the studies on vaccination approaches against pneumococcal infection in patients with multiple myeloma. Conclusions. The article presents modern epidemiological data, as well as the results of original studies of clinical and immunological aspects of pneumococcal vaccination in patients with MM receiving new targeted agents and immunotherapy. The effectiveness of the use of the conjugated pneumococcal vaccine in patients treated with MM with bortezomib, lenalidomide, and ixazomib was indicated. An independent protective effect of pneumococcal vaccination has been shown as a preventive measure in a cohort of patients with MM, against the background of treatment with new targeted drugs.
Highlights
A continuous data review method was used to evaluate the studies on vaccination approaches against pneumococcal infection in patients with multiple myeloma
The effectiveness of the use of the conjugated pneumococcal vaccine in patients treated with MM with bortezomib, lenalidomide, and ixazomib was indicated
An independent protective effect of pneumococcal vaccination has been shown as a preventive measure in a cohort of patients with MM, against the background of treatment with new targeted drugs
Summary
Введение Инвазивные формы пневмококковой инфекции являются жизнеугрожающими, при этом вакциноуправляемыми у пациентов с иммуносупрессией. Восприимчивых к инвазивным инфекциям, вызванным S. pneumoniae, выделяются пациенты с онкогематологическими заболеваниями, а также реципиенты гемопоэтических стволовых клеток. В последнее время отмечается увеличение количества пациентов, получающих таргетные лекарственные средства, моноклональные антитела и новые агенты при лечении аутоиммунных, ревматологических заболеваний и злокачественных новообразований. Что инвазивные пневмококковые инфекции обычно протекают более тяжело в обозначенных группах высокого риска в сравнении с общей популяцией иммунокомпетентных лиц [1,2,3,4,5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
